India  

Haryana starts clinical trials for coronavirus vaccine 'covaxin' at PGIMS Rohtak

Video Credit: ANI - Duration: 02:32s - Published
Haryana starts clinical trials for coronavirus vaccine 'covaxin' at PGIMS Rohtak

Haryana starts clinical trials for coronavirus vaccine 'covaxin' at PGIMS Rohtak

Haryana started clinical trials for coronavirus vaccine 'covaxin' at Pandit Bhagwat Dayal Sharma Post Graduate Institute of Medical Sciences (PGIMS) in Rohtak.

Vice-Chancellor OP Kalra said, "Today, we enrolled three subjects for human trails in the primary results they tolerated the vaccine very well, no adverse effect has been reported." State Health Minister Anil Vij also commented on the trail of vaccine and said it is really good news.


You Might Like


Related videos from verified sources

Covid update: India on herd immunity; Kolkata extends flight ban till Aug 15 [Video]

Covid update: India on herd immunity; Kolkata extends flight ban till Aug 15

From India stating that herd immunity is not a strategic option yet, to Kolkata extending flight ban, here are the top updates on coronavirus. Health Ministry on Thursday said herd immunity is not a..

Credit: HT Digital Content     Duration: 03:30Published
First Phase 3 Coronavirus Vaccine Candidate Begins Testing in US [Video]

First Phase 3 Coronavirus Vaccine Candidate Begins Testing in US

First Phase 3 Coronavirus Vaccine Candidate Begins Testing in US The experimental vaccine, developed by Moderna and the National Institute of Allergy and Infectious Diseases, began Phase 3 trials on..

Credit: Wibbitz Top Stories     Duration: 01:05Published
News Anchor Makes History By Receiving First Shot In US Phase 3 Trial Of Coronavirus Vaccine [Video]

News Anchor Makes History By Receiving First Shot In US Phase 3 Trial Of Coronavirus Vaccine

Scientists have entered Phase 3 clinical trials, the most advanced stage of testing, of a coronavirus vaccine in the United States and one CBS anchor became the first volunteer to get the injection...

Credit: KCAL 9 CBS LA     Duration: 02:07Published